- Home
- SLNO vs KNSA Comparison
SLNO vs KNSA Comparison
Compare SLNO & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLNO | KNSA |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.6B |
| IPO Year | 2014 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SLNO | KNSA |
|---|---|---|
| Price | $50.02 | $40.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 6 |
| Target Price | ★ $110.90 | $51.33 |
| AVG Volume (30 Days) | ★ 1.5M | 330.1K |
| Earning Date | 11-04-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.47 |
| Revenue | $98,675,000.00 | ★ $597,973,000.00 |
| Revenue This Year | N/A | $62.63 |
| Revenue Next Year | $155.86 | $29.93 |
| P/E Ratio | ★ N/A | $86.85 |
| Revenue Growth | N/A | ★ 55.68 |
| 52 Week Low | $41.50 | $17.82 |
| 52 Week High | $90.32 | $42.98 |
Technical Indicators
Market Signals| Indicator | SLNO | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 45.66 | 48.40 |
| Support Level | $47.80 | $39.61 |
| Resistance Level | $53.10 | $42.32 |
| Average True Range (ATR) | 2.32 | 1.52 |
| MACD | 0.83 | -0.22 |
| Stochastic Oscillator | 64.42 | 22.55 |
Price Performance
Historical ComparisonAbout SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.